Corvus Pharmaceuticals, Inc. (CRVS) Income Statement Analysis

See more : Telecure Technologies Inc. (TELE.CN) Income Statement Analysis – Financial Results

Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Denali Bancorporation, Inc. (DENI) Income Statement Analysis – Financial Results
Pharos Energy plc (PHAR.L) Income Statement Analysis – Financial Results
NEXT Biometrics Group ASA (NEXT.OL) Income Statement Analysis – Financial Results
HUTCHMED (China) Limited (0013.HK) Income Statement Analysis – Financial Results
Leadway Technology Investment Group Limited (2086.HK) Income Statement Analysis – Financial Results

Corvus Pharmaceuticals, Inc. (CRVS)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.corvuspharma.com

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	151.00K	367.00K	460.00K	632.00K	743.00K	847.00K	842.00K	594.00K	148.00K	0.00
Gross Profit	-151.00K	-367.00K	-460.00K	-632.00K	-743.00K	-847.00K	-842.00K	-594.00K	-148.00K	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	16.53M	24.47M	29.12M	31.83M	37.98M	38.59M	46.31M	29.36M	11.35M	41.46K
General & Administrative	6.88M	8.10M	9.52M	11.93M	10.88M	10.64M	10.22M	7.62M	2.42M	134.18K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	6.88M	8.10M	9.52M	11.93M	10.88M	10.64M	10.22M	7.62M	2.42M	134.18K
Other Expenses	0.00	587.00K	235.00K	37.46M	0.00	0.00	0.00	0.00	-17.60M	0.00
Operating Expenses	23.41M	32.57M	38.63M	43.76M	48.85M	49.22M	56.52M	36.98M	13.77M	175.64K
Cost & Expenses	23.41M	32.57M	38.63M	43.76M	48.85M	49.22M	56.52M	36.98M	13.77M	175.64K
Interest Income	0.00	654.00	0.00	540.00K	2.18M	2.28M	861.00K	601.00K	35.00K	0.00
Interest Expense	1.58M	654.00K	15.00K	540.00K	2.18M	2.28M	0.00	601.00K	0.00	0.00
Depreciation & Amortization	151.00K	367.00K	460.00K	632.00K	743.00K	847.00K	842.00K	594.00K	148.00K	175.64K
EBITDA	-26.88M	-40.94M	-42.78M	-5.36M	-48.85M	-46.09M	-54.82M	-35.78M	-31.19M	14.64K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-23.41M	-32.57M	-38.63M	-43.76M	-48.85M	-49.22M	-56.52M	-36.98M	-13.77M	-175.64K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-3.62M	-8.74M	-4.61M	37.77M	2.18M	2.28M	861.00K	601.00K	-17.57M	0.00
Income Before Tax	-27.03M	-41.31M	-43.24M	-6.00M	-46.67M	-46.94M	-55.66M	-36.38M	-31.34M	-175.64K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	8.74M	-5.04M	-1.17M	-2.93M	2.28M	-842.00K	-594.00K	-35.00K	0.00
Net Income	-27.03M	-50.05M	-38.20M	-4.82M	-43.75M	-46.94M	-55.66M	-36.38M	-31.34M	-175.64K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.56	-1.08	-0.91	-0.16	-1.49	-1.71	-2.72	-2.36	-1.54	-1.03
EPS Diluted	-0.56	-1.08	-0.91	-0.16	-1.49	-1.71	-2.72	-2.36	-1.54	-1.03
Weighted Avg Shares Out	48.03M	46.55M	41.85M	29.48M	29.35M	27.51M	20.49M	15.42M	20.41M	170.00K
Weighted Avg Shares Out (Dil)	48.03M	46.55M	41.85M	29.48M	29.35M	27.51M	20.49M	15.42M	20.41M	170.28K

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024globenewswire.com

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

May 2, 2024globenewswire.com

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

May 2, 2024globenewswire.com

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to...

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

April 17, 2024zacks.com

The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

April 9, 2024globenewswire.com

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

April 1, 2024zacks.com

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...